C-Bridge Capital, a US$700 million-under-management healthcare private equity fund in China, has teamed up with Tianjin-based traditional Chinese medicine company Tasly Holding Group to invested US$150 million in a newly created Chinese drug developer resulted from a merger of two pharmaceutical firms.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 2 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.Register Basic Account
Subscribe for an annual subscription!
Enjoy comprehensive and exclusive data you can't find elsewhere!More Info
Already have an account or paid subscription?